Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. decreased its position in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 10.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,455 shares of the company’s stock after selling 1,999 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.13% of Greenwich LifeSciences worth $236,000 as of its most recent SEC filing.

Separately, Rhumbline Advisers bought a new position in shares of Greenwich LifeSciences in the second quarter worth $117,000. Institutional investors own 4.16% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright lifted their price objective on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Friday, August 23rd.

Greenwich LifeSciences Trading Up 2.0 %

Shares of NASDAQ:GLSI opened at $12.52 on Friday. The company has a 50 day moving average of $13.62 and a 200-day moving average of $14.42. The firm has a market cap of $164.58 million, a P/E ratio of -15.65 and a beta of 1.61. Greenwich LifeSciences, Inc. has a twelve month low of $8.00 and a twelve month high of $21.44.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.